Zobrazeno 1 - 10 of 21 pro vyhledávání: '"Randy Robinson"'
7
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
Autor: Vivek Subbiah, Louie Naumovski, Hua Fang, Antoine Hollebecque, George D. Demetri, Chris Chen, Victor M. Villalobos, Jason J. Luke, Alexander I. Spira, Padmanee Sharma, Dominic W. Lai, James P. Allison, James W. Purcell, Anthony W. Tolcher, Randy Robinson, Akshanth R. Polepally, Huibin Yue, John D. Powderly
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 27(13)
Purpose:Leucine-rich repeat containing 15 (LRRC15) is expressed on stromal fibroblasts in the tumor microenvironment of multiple solid tumor types and may represent an interesting target for therapy, particularly in patients with sarcomas where LRRC1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7b06683d20ddbed17cd79560bf6e4f0
https://pubmed.ncbi.nlm.nih.gov/33820780
Zobrazit plný text záznamu
8
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
Autor: Randy Robinson, Wanda Castro-Borrero, Sami Fam, Becky Parks, Douglas L. Arnold, Shan Xiao, Ludwig Kappos, Joan Holman, Stanley Cohan
Publikováno v: Therapeutic Advances in Neurological Disorders
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: EXTEND (NCT01797965), an open-label extension study, evaluated the safety and efficacy of daclizumab beta in participants with relapsing multiple sclerosis (MS) who had completed the randomized DECIDE study. Methods: Eligible participants
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6526dfefb7748df92622f3164af30d8b
https://pubmed.ncbi.nlm.nih.gov/33737954
Zobrazit plný text záznamu
9
Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta
Autor: Kimberly Umans, Jacob Elkins, Gulden Ozen, Lahar Mehta, Randy Robinson
Publikováno v: International Journal of MS Care. 19:141-147
Background: For patients with relapsing-remitting multiple sclerosis (RRMS) undergoing continuous immunomodulatory therapy, understanding whether vaccinations can be performed safely and effectively is important. We tested the immune response to inac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad2b115caf01e17f1858b297670eb1d0
https://doi.org/10.7224/1537-2073.2016-026
Zobrazit plný text záznamu
10
Phase I study of the antibody-drug conjugate ABBV-321 in patients with non-small cell lung cancer and squamous head and neck cancer with overexpression of the epidermal growth factor receptor
Autor: Louie Naumovski, JuDee Fischer, Peter Ansell, Christine M. Bestvina, Joseph Thaddeus Beck, Amber Wong, Benedito A. Carneiro, Janet Yikai Jin, Einat Shacham Shmueli, Hui K Gan, Randy Robinson, Kyriakos P. Papadopoulos
Publikováno v: Journal of Clinical Oncology. 38:TPS3649-TPS3649
TPS3649 Background: ABBV-321 (serclutamab talirine) is an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate that consists of a humanized immunoglobulin G1 anti-EGFR monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f3cc6e72fe4887f6183109357f768ce0
https://doi.org/10.1200/jco.2020.38.15_suppl.tps3649
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje